PR
Prelude Therapeutics Incorporated
PRLD · NASDAQ
$5.30 -0.19% (-$0.01)
1M +9.73%
Market Cap $416.0M
P/E Ratio -
Div. Yield -
ROE 75.35%
Bulios Fair Price
$3.26
38.5% downside
Current Price
$5.3
Undervalued Fair Value Overvalued
According to Bulios Fair Price, PRLD is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
33 /100
Expensive P/S 18.55x
P/B 3.11x
P/E N/A
Growth
0 /100
Declining Book val. growth 29.45%
EPS growth N/A
Rev. growth N/A
Profitability
20 /100
Weak Gross margin 98.26%
Net margin 269.75%
FCF margin 148.30%
Quality
2 /100
Poor ROIC 43.74%
ROE 75.35%
Asset turnover 0.12x
Debt
100 /100
Low Debt/Equity 0.13x
Current ratio 4.07x
Int. coverage N/A
Stability
77 /100
Stable Beta 0.96x
EPS volatility 6.10%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PRLD
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Krishna Vaddi
Employees
79
Headquarters
Wilmington
Upcoming events
11 NOV
Earnings
Upcoming earnings report